Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Adult hypophosphatasia treated with reduced frequency of teriparatide dosing..
J Musculoskelet Neuronal Interact. 21(4), 584-589.
(2021). Current and emerging osteoporosis pharmacotherapy for women: state of the art therapies for preventing bone loss..
Expert Opin Pharmacother. 20(9), 1123-1134.
(2019). Drug holidays in osteoporosis treatment: mind the gaps!.
Osteoporos Int. 30(12), 2523-2524.
(2019). New therapeutic targets for osteoporosis..
Maturitas. 120, 1-6.
(2019). Multiple Vertebral Fractures Following Denosumab Discontinuation: Are We Exaggerating?.
Calcif Tissue Int. 103(1), 107-108.
(2018). THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis..
Eur J Endocrinol. 179(1), R31-R45.
(2018). Increased CD14+ and decreased CD14- populations of monocytes 48 h after zolendronic acid infusion in breast cancer patients..
Osteoporos Int. 28(3), 991-999.
(2017).
(2016).
Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment..
Expert Opin Ther Targets. 19(3), 299-306.
(2015). Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers..
Metabolism. 64(10), 1291-7.
(2015). Denosumab versus zoledronic acid in patients previously treated with zoledronic acid..
Osteoporos Int. 26(10), 2521-7.
(2015). Osteoporosis after renal transplantation..
Int Urol Nephrol. 47(3), 503-11.
(2015). Treatment of multiple myeloma bone disease: experimental and clinical data..
Expert Opin Biol Ther. 15(2), 213-30.
(2015).
(2014).
Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment..
Osteoporos Int. 24(7), 2127-32.
(2013).
(2013).
(2013). Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass..
Bone. 50(5), 1130-4.
(2012). Impact of long-term cinacalcet, ibandronate or teriparatide therapy on bone mineral density of hemodialysis patients: a pilot study..
Am J Nephrol. 36(3), 238-44.
(2012). Normal bone turnover markers in a patient with active Paget's disease of bone: response to treatment with zoledronic acid..
Endokrynol Pol. 63(4), 312-5.
(2012). Possible zoledronic acid-induced dermatomyositis..
Clin Exp Dermatol. 37(3), 309-11.
(2012). Quality of life in breast cancer patients with bisphosphonate-related osteonecrosis of the jaws and patients with head and neck cancer: a comparative study using the EORTC QLQ-C30 and QLQ-HN35 questionnaires..
Anticancer Res. 32(8), 3527-34.
(2012). The role of cytokines and adipocytokines in zoledronate-induced acute phase reaction in postmenopausal women with low bone mass..
Clin Endocrinol (Oxf). 77(6), 816-22.
(2012).
(2012). Aromatase inhibitors in post-menopausal endometriosis..
Reprod Biol Endocrinol. 9, 90.
(2011).